OM DENNE EPISODE
If BPC-157, TB-500, KPV, MOTS-C and similar peptides are so interesting, why don't we have giant randomized human trials?
This episode looks at the less dramatic—and more important—answer: clinical trials require a sponsor, regulatory strategy, manufacturing package, defined indication, safety program, and a very large amount of money. For old, easily copied, poorly protected, or commercially fragmented compounds, the incentive to fund definitive trials may be weak.
John also explains why that does not excuse the evidence gap. "No Phase 3 trial" is not proof that a peptide works. It simply means confidence should remain limited until better evidence exists.
Educational only. Not medical advice.
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af Peptides Explained.
ANDRE EPISODE I DENNE PODCAST
Download The Peptide App at ThePeptide.App/Explained
For more information on research peptides check out PeptidesExplained.info/OfflinePeptides
A peptide…in a pill?
Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasi…
Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease.
But is a vial labeled "Follistatin-344" equivalent to the therapy used in thos…
Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them?
John breaks down glutathione biolo…
For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides
Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily.
This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semagluti…
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra John Garrett, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
